Pharma BD Deal Intelligence

Sanofi-Synthelabo SA / Aventis SA

2004 · Acquisition/Merger · $65.0B · Complete

Announcement Sentiment

Neutral / mixed

Outcome Score

Worked — the deal delivered on its rationale.

Sanofi-Synthelabo acquired Aventis for approximately EUR 55.2 billion ($65 billion) after an initial hostile bid of EUR 47.8 billion was rejected. The revised friendly offer comprised five Sanofi shares for each Aventis share plus EUR 120 in cash, creating the world's third-largest pharmaceutical company.

Key facts

Announced Jan 26, 2004
Closed Aug 20, 2004
Deal value $65.0B
Deal type Acquisition/Merger
Therapeutic area Cardiovascular, Immunology, Metabolic, Oncology
Indications Thrombosis, Venous Thromboembolism, Cancer, Diabetes
Key assets Plavix (clopidogrel), Lovenox (enoxaparin), Taxotere (docetaxel), Lantus (insulin glargine), Allegra (fexofenadine)
Mechanism Antiplatelet agent, Low molecular weight heparin, Taxane antineoplastic, Long-acting insulin analog

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals